Literature DB >> 32945013

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.

Kristine Karkoska1, Charles T Quinn1,2, Kelly Clapp1, Patrick T McGann1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32945013     DOI： 10.1002/ajh.26002

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

Review 1.  Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.

Authors:  Debra L Stevens; Meri Hix; Brooke L Gildon
Journal:  J Pharm Technol       Date:  2021-04-19

Review 2.  Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

Authors:  Maurice H Dick; Arowa Abdelgadir; Vaishnavi Vijaya Kulkarni; Hamna Akram; Abanti Chatterjee; Sushil Pokhrel; Safeera Khan
Journal:  Cureus       Date:  2022-05-11

Review 3.  Research in Sickle Cell Disease: From Bedside to Bench to Bedside.

Authors:  Gabriel Salinas Cisneros; Swee Lay Thein
Journal:  Hemasphere       Date:  2021-06-01

4.  P-selectin deficiency promotes liver senescence in sickle cell disease mice.

Authors:  Ravi Vats; Tomasz W Kaminski; Eun-Mi Ju; Tomasz Brozska; Egemen Tutuncuoglu; Jesús Tejero; Enrico M Novelli; Prithu Sundd; Tirthadipa Pradhan-Sundd
Journal:  Blood       Date:  2021-05-13       Impact factor: 25.476
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.